SCHEMBL1997374

SCHEMBL1997374

CC(C)(C)OC(=O)N1CCC2(CC1)CNc1ncccc12

nearest known ligand 0.49

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.49
GPR119 Q8TDV5 3/20 0.46
KCNH2 Q12809 3/20 0.44
OPRD1 P41143 1/20 0.43
OPRK1 P41145 1/20 0.43
AKT1 P31749 1/20 0.43
DTYMK P23919 1/20 0.43
HDAC1 Q13547 2/20 0.43
HDAC8 Q9BY41 2/20 0.43
HDAC6 Q9UBN7 2/20 0.43
NAMPT P43490 1/20 0.43
MAPK1 P28482 1/20 0.40
USP30 Q70CQ3 1/20 0.40
IDH1 O75874 1/20 0.40
GRM5 P41594 1/20 0.40
CHRM4 P08173 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29640113 1.00 POLB (0.49) POLBGPR119KCNH2OPRD1OPRK1
SCHEMBL29644487 0.82 MAPK1 (0.51) POLBGPR119OPRD1OPRK1HDAC1
SCHEMBL1689626 0.82 MAPK1 (0.51) POLBGPR119OPRD1OPRK1HDAC1
SCHEMBL12566957 0.81 POLB (0.49) POLBGPR119OPRD1OPRK1AKT1
SCHEMBL28785987 0.81 OTUD7B (0.42) KCNH2HDAC1MAPK1IDH1CHRM4
SCHEMBL1435080 0.81 POLB (0.48) POLBGPR119KCNH2OPRD1OPRK1
SCHEMBL1435078 0.81 POLB (0.48) POLBGPR119KCNH2OPRD1OPRK1
SCHEMBL29416284 0.78 KCNH2 (0.61) POLBGPR119KCNH2OPRD1OPRK1
SCHEMBL769742 0.77 USP2 (0.45) POLBGPR119MAPK1USP30
SCHEMBL1995317 0.77 NAMPT (0.45) POLBGPR119NAMPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114450271-B Ureas, amino and substituted heteroaryl compounds for Cbl-b inhibition 纽力克斯治疗公司 2024-09-20 CN disclosed
CN-114450271-A Ureas, amino and substituted heteroaryl compounds for Cbl-b inhibition 纽力克斯治疗公司 2022-05-06 CN disclosed
US-7960401-B2 Spiropiperidine derivatives for controlling pests SYNGENTA CROP PROTECTION, INC. (US) 2011-06-14 US disclosed
US-7960401-B2 Spiropiperidine derivatives for controlling pests SYNGENTA CROP PROTECTION, INC. (US) 2011-06-14 US disclosed
US-7960401-B2 Spiropiperidine derivatives for controlling pests SYNGENTA CROP PROTECTION, INC. (US) 2011-06-14 US disclosed
EP-1694677-B1 SPIROPIPERIDINE DERIVATIVES FOR CONTROLLING PESTS SYNGENTA PARTICIPATIONS AG (CH) 2009-12-02 EP disclosed
US-20070135408-A1 Spiropiperidine derivatives for controlling pests SYNGENTA CROP PROTECTION, INC. 2007-06-14 US disclosed
US-20070135408-A1 Spiropiperidine derivatives for controlling pests SYNGENTA CROP PROTECTION, INC. 2007-06-14 US disclosed
US-20070135408-A1 Spiropiperidine derivatives for controlling pests SYNGENTA CROP PROTECTION, INC. 2007-06-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070135408-A1 Spiropiperidine derivatives for controlling pests CHRM1, CHRM2, RER1 POLB 4227/4885GPR119 2612/4885KCNH2 348/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.